WebPosted 2:19:44 AM. Ionis Pharmaceuticals, Inc., is headquartered in Carlsbad, California, with offices in Boston…See this and similar jobs on LinkedIn. WebFrom the 1Core Antisense Research, 2Development Communication, and 3Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, California, USA Edited by Karin Musier-Forsyth Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA-targeted drugs including eight single-strand antisense drugs …
Antisense technology: A review - PubMed
WebOur antisense therapies are disrupting diseases and, we hope, changing their course—from the rarest of conditions, to those that impact millions of people. And as we … Web26 jul. 2024 · This commitment extends across multiple modalities, including antisense oligonucleotides, as with BIIB080,” said Alfred Sandrock, Jr., M.D., Ph.D., Head of Research and Development at Biogen. “Biogen is encouraged by the results of this trial, and we look forward to our continued research in future clinical studies with this promising … iman business school
Antisense Oligos May Hit “Undruggable” YAP1 Cancer Discovery ...
Web19 sep. 2024 · We recently showed that translation can be enhanced by antisense oligonucleotides (ASOs) that target upstream open reading frames. Here we report the … WebThe Ionis antisense pipeline Our antisense technology platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 potential first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. Web1 jun. 2024 · During the virtual American Association for Cancer Research Annual Meeting 2024, held April 10–15, MacLeod presented preclinical findings on ION537. To develop the drug, his team first did pilot in vivo studies showing that subcutaneously injected ASOs depleting YAP1 in two mouse models of HCC caused tumor regression and increased … list of groundnuts